Anti-PCK1/PEPC antibody (ab115693)
- Datasheet
- References (1)
- Protocols
Overview
-
Product name
Anti-PCK1/PEPC antibody
See all PCK1/PEPC primary antibodies -
Description
Goat polyclonal to PCK1/PEPC -
Host species
Goat -
Tested applications
Suitable for: ELISA, IHC-Pmore details -
Species reactivity
Reacts with: Human
Predicted to work with: Mouse, Rat, Cow, Dog, Pig, Xenopus laevis
-
Immunogen
Synthetic peptide corresponding to Human PCK1/PEPC aa 513-524 (internal sequence) (Cysteine residue).
Sequence:HVNWFRKDKEGK
Database link: NP_002582.3 -
Positive control
- Human kidney and liver tissues.
-
General notes
This product was previously labelled as PCK1
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles. -
Storage buffer
pH: 7.30
Preservative: 0.02% Sodium azide
Constituents: 99% Tris buffered saline, 0.5% BSA -
Concentration information loading... -
Purity
Protein G purified -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Positive Controls
-
Recombinant Protein
Applications
Our Abpromise guarantee covers the use of ab115693 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| ELISA | 1/8000. | |
| IHC-P | Use a concentration of 2 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
Target
-
Function
Catalyzes the conversion of oxaloacetate (OAA) to phosphoenolpyruvate (PEP), the rate-limiting step in the metabolic pathway that produces glucose from lactate and other precursors derived from the citric acid cycle. -
Tissue specificity
Major sites of expression are liver, kidney and adipocytes. -
Pathway
Carbohydrate biosynthesis; gluconeogenesis. -
Involvement in disease
Defects in PCK1 are the cause of cytosolic phosphoenolpyruvate carboxykinase deficiency (cytosolic PEPCK deficiency) [MIM:261680]. PEPCK deficiency is a metabolic disorder resulting from impaired gluconeogenesis. It is a rare disease with less than 10 cases reported in the literature. Clinical characteristics include hypotonia, hepatomegaly, failure to thrive, lactic acidosis and hypoglycemia. Autoposy reveals fatty infiltration of both the liver and kidneys. The disorder is transmitted as an autosomal recessive trait. -
Sequence similarities
Belongs to the phosphoenolpyruvate carboxykinase [GTP] family. -
Post-translational
modificationsAcetylation is increased on addition of glucose and appears to regulate the protein stability. -
Cellular localization
Cytoplasm. - Information by UniProt
-
Database links
- Entrez Gene: 282855 Cow
- Entrez Gene: 403560 Dog
- Entrez Gene: 5105 Human
- Entrez Gene: 18534 Mouse
- Entrez Gene: 100144531 Pig
- Entrez Gene: 362282 Rat
- Entrez Gene: 379844 Xenopus laevis
- Omim: 614168 Human
see all -
Alternative names
- cytosolic [GTP] antibody
- GTP antibody
- PCK1 antibody
see all
Images
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PCK1/PEPC antibody (ab115693)ab115693, at 2µg/ml, staining PCK1//PEPC in Formalin-fixed, Paraffin-embedded Human Kidney tissue by Immunohistochemistry followed by biotinylated secondary antibody, alkaline phosphatase-streptavidin and chromogen.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PCK1/PEPC antibody (ab115693)ab115693, at 2µg/ml, staining PCK1/PEPC in Formalin-fixed, Paraffin-embedded Human Liver tissue by Immunohistochemistry followed by biotinylated secondary antibody, alkaline phosphatase-streptavidin and chromogen.
Protocols
Datasheets and documents
References
This product has been referenced in:
- Zhao L et al. PPAR signaling pathway in the first trimester placenta from in vitro fertilization and embryo transfer. Biomed Pharmacother 118:109251 (2019). Read more (PubMed: 31351426) »
